Boston Scientific Stock After the Cyberattack and Watchman Slowdown: Why 13.4x Forward Earnings Sets Up a $54 Base Case Before October 28 Earnings

Table of Contents

Boston Scientific (NYSE: BSX) shares have fallen sharply in 2026. The shares closed at $45.42 in the latest session, down roughly 57% from a 52-week high of $105.65. Three separate shocks did the damage: an electrophysiology franchise that lost U.S. share to Medtronic, Johnson & Johnson and Abbott faster than management expected; a sharp slowdown in stand-alone WATCHMAN left atrial appendage closure procedures; and, most recently, an August 25 cyberattack that disrupted manufacturing and order shipments worldwide. Full-year guidance has been cut twice, and in its September 7 filing the company said it is now unlikely to meet even the reduced numbers.

That is the bear story, and it is real. But the price now discounts a great deal of it. At $45.42, Boston Scientific trades at 13.4x the consensus forward EPS estimate of $3.39, at less than half the price it fetched at its 52-week high. This article asks a specific question: what is Boston Scientific stock worth after the cyberattack, once the one-time disruption is separated from the structural slowdown? The company will answer part of that on October 28, 2026, when it reports third-quarter results and updates its 2026 outlook.

Our view rests on three investment points.

1. Most of the company is still growing. In the second quarter, before the cyber incident, net sales rose 7.5% to $5.442 billion. Interventional Cardiology & Vascular Therapies grew about 13%, Neuromodulation about 13%, Interventional Oncology & Embolization about 13% and Endoscopy about 8%. CEO Mike Mahoney told investors in July that the roughly three-quarters of the business outside the two problem franchises is growing about 6%.

2. Earnings quality and cash generation are intact. GAAP operating income in Q2 rose 44% to $1.178 billion, adjusted EPS was $0.86 versus $0.75 a year earlier, and operating cash flow for the first half was $1.822 billion. The company retired roughly 40 million shares through a $2 billion accelerated share repurchase in May–June and launched a restructuring program targeting about $500 million in gross annual savings.

3. The cyberattack is a timing problem, not a demand problem. The September 8-K says major distribution centers were already shipping at or above normal levels, sterilization was operational and manufacturing had resumed at most sites. The company expects to recover “some portion” of the lost revenue and does not expect a material impact on its long-term financial condition. If that holds, Q3 and Q4 2026 numbers will look ugly, but 2027 earnings power should be largely unaffected.

The rest of this article walks through the business model and segment mix, the electrophysiology and structural heart industry dynamics that drove the de-rating, the durability of Boston Scientific’s moats, the financial record, a step-by-step valuation with bull/base/bear scenarios, the key risks, and a concrete entry and exit plan ahead of the October 28 report.

1. Company Overview: How Boston Scientific Makes Money

Boston Scientific is a Marlborough, Massachusetts-based maker of minimally invasive medical devices. It sells implants, catheters, ablation systems, stents and capital equipment to hospitals and ambulatory surgery centers in more than 100 countries. Revenue is overwhelmingly recurring and procedure-driven: the company earns money every time a physician performs a cardiac ablation, implants a WATCHMAN device, places a stent, or treats a kidney stone with one of its tools. Capital equipment such as mapping systems and generators matters mostly because it pulls through high-margin disposable catheters for years afterward.

The company reports two segments. Cardiovascular (about two-thirds of sales) includes electrophysiology, WATCHMAN, interventional cardiology and vascular therapies, cardiac rhythm management (pacemakers and defibrillators) and interventional oncology. MedSurg includes Endoscopy, Urology and Neuromodulation.

Revenue breakdown — Q2 2026 (from the company’s 10-Q)

Business	Q2 2026 Sales	Q2 2025 Sales	YoY Change	Share of Total
Interventional Cardiology & Vascular Therapies	$1,333M	$1,178M	+13.2%	24.5%
Electrophysiology	$916M	$840M	+9.0%	16.8%
Endoscopy	$793M	$737M	+7.6%	14.6%
Urology	$684M	$676M	+1.1%	12.6%
Cardiac Rhythm Management	$585M	$590M	-0.8%	10.7%
WATCHMAN	$507M	$486M	+4.3%	9.3%
Neuromodulation	$341M	$303M	+12.7%	6.3%
Interventional Oncology & Embolization	$283M	$251M	+12.7%	5.2%
Total	$5,442M	$5,061M	+7.5%	100%

Geographically, the U.S. contributed $3.426 billion (63%) of Q2 sales and grew 6.2%. Asia-Pacific grew 11.2% to $878 million, and Latin America and Canada grew 22.4% to $206 million. International growth is increasingly important to the story: international electrophysiology sales rose 23% year over year in Q2, while U.S. electrophysiology sales grew only about 3%.

The franchises that built Boston Scientific’s premium valuation in 2023–2025 were FARAPULSE, its pulsed field ablation (PFA) system for atrial fibrillation, and WATCHMAN, its left atrial appendage closure (LAAC) device for stroke prevention in AFib patients who cannot tolerate long-term blood thinners. In 2025, WATCHMAN alone generated $1.96 billion in sales, up nearly 30%, and the company’s total revenue grew 19.9% to $20.074 billion. Those two franchises are exactly where the 2026 disappointment came from.

Customers and position. Boston Scientific’s customers are hospital systems, integrated delivery networks, group purchasing organizations and, increasingly, ambulatory surgery centers. It competes against Medtronic, Abbott, Johnson & Johnson MedTech and Stryker across overlapping categories. It is a top-tier player in electrophysiology, LAAC, coronary interventions, endoscopy and urology.

Ownership and governance. Boston Scientific is widely held by institutional investors, and insider ownership is small, as is typical for a mega-cap medtech company. Leadership is in transition: on October 7 the company announced that Joe Fitzgerald, the Cardiovascular group president and a 36-year company veteran, will become Chief Operating Officer on January 1, 2027. Separately, Art Butcher, who leads MedSurg and Asia Pacific, will retire effective the same date. Investors should read the COO appointment as a sign that the board wants a seasoned cardiovascular operator closer to day-to-day execution while the EP and WATCHMAN issues are worked through.

Capital deployment in 2026 has been unusually active:
– Penumbra acquisition (pending): announced January 15, 2026 at $374 per share, about $14.5 billion in enterprise value, roughly 73% cash and 27% stock. Penumbra shareholders approved the deal on May 6. The FTC issued a Second Request on March 16, and the company said in its 10-Q that it expects to close in the second half of 2026, subject to regulatory clearance.
– MiRus investment: a $1.5 billion cash payment for about a 33.75% stake in MiRus LLC, plus an exclusive option to buy its SIEGEL balloon-expandable TAVR business for another $3 billion upon clinical and regulatory milestones.
– Nalu Medical: acquisition completed January 27, 2026 for about $523 million net of cash, adding peripheral nerve stimulation to Neuromodulation.
– Buybacks: a $2 billion accelerated share repurchase with JPMorgan that retired about 40 million shares. Shares outstanding fell to 1.45 billion.

2. Industry Analysis: Electrophysiology, Structural Heart and the Medtech Cycle

This section matters most. Boston Scientific’s de-rating is not a story about a broken company; it is a story about two very attractive markets maturing faster, and becoming more competitive faster, than the market priced in 2025.

2-1. Market Size and Growth Trajectory

Electrophysiology (EP). EP covers diagnosis and treatment of heart rhythm disorders, chiefly atrial fibrillation (AFib), through catheter ablation. According to Stifel commentary reported by MedTech Dive in April 2026, the global EP market is about $16 billion and growing at a mid- to high-teens rate.

The growth comes from two forces. First, AFib prevalence keeps rising with population aging, obesity and better detection through wearables. Second, ablation is moving earlier in the treatment pathway: rather than cycling patients through years of antiarrhythmic drugs, physicians increasingly ablate first. Boston Scientific’s own AVANT GUARD trial, published in the New England Journal of Medicine, tested Farawave PFA against drug therapy as a first-line treatment for persistent AFib, randomizing 310 patients 2:1 (207 PFA, 103 antiarrhythmic drugs), and showed 12-month primary effectiveness of about 56% versus 30% for drugs. Boston Scientific estimates the persistent AFib first-line opportunity alone could be a $1 billion market by 2028.

Left atrial appendage closure (LAAC). WATCHMAN built the U.S. LAAC market over the past decade. Most AFib-related strokes originate from clots that form in the left atrial appendage; sealing it off offers an alternative to lifelong oral anticoagulation. WATCHMAN’s $1.96 billion of 2025 sales shows how large the category has become. Before the CHAMPION-AF results, the company had guided for about 20% WATCHMAN market growth in 2026.

Where are we in the cycle? EP has moved from early growth into acceleration, and in the U.S. it is now in a competitive maturation phase for PFA specifically. Management said in July that PFA already accounts for 80–85% of U.S. ablation procedures. That is the key fact behind the slowdown: in 2024–2025, Boston Scientific’s EP growth benefited both from overall procedure growth and from rapid conversion of thermal ablation (radiofrequency and cryo) to PFA, where FARAPULSE was the early leader. With conversion largely complete in the U.S., future growth must come from procedure volume and share, not technology substitution. Outside the U.S., conversion is earlier — which is why international EP grew 23% in Q2.

LAAC, by contrast, is in a reimbursement-and-evidence transition. Procedures performed together with ablation (concomitant procedures) are growing, but stand-alone WATCHMAN procedures declined in the low-to-mid teens percent year over year in the U.S. in Q2, according to earnings call coverage.

2-2. Structural Growth Drivers

Driver 1: Aging populations and the AFib epidemic. AFib is strongly age-linked. As baby boomers age into their 70s and 80s, the pool of patients needing rhythm control and stroke prevention grows almost mechanically. This driver is slow, predictable and long-lived. It doesn’t depend on any single product cycle and it supports both EP and LAAC volumes for a decade or more. For Boston Scientific, it means the underlying demand for its most important franchises compounds even in years when share shifts against it. The 2026 problem is competitive allocation of a growing pie, not a shrinking pie. Short-term, this driver cannot offset share loss; long-term, it strongly supports the case that a company with a competitive, well-supported PFA platform will keep growing EP revenue.

Driver 2: Earlier intervention and expanding indications. The clinical trend is toward treating AFib earlier and more aggressively, because evidence shows that rhythm control is more effective before the atria remodel. AVANT GUARD supports first-line PFA in persistent AFib; Medtronic’s PulseSelect has an approval for persistent AFib, and new PFA catheters are pushing into ventricular tachycardia (Medtronic’s Sphere-9 received FDA breakthrough device designation and a U.S. pivotal trial approval for VT). Each indication expansion enlarges the addressable procedure pool. For Boston Scientific, the opportunity is to use its installed base of FARAPULSE users and its own mapping software to defend share as procedures expand. In the short term, competitor launches take share; in the long term, indication expansion lifts every serious PFA player.

Driver 3: Concomitant procedures and workflow efficiency. Hospitals are capacity-constrained. Labs, anesthesiologists and electrophysiologists are scarce, and that constrains stand-alone LAAC volumes — management explicitly cited hospital capacity constraints and shifting procedure prioritization in Q1. The flip side is that combining ablation and LAAC in a single session is efficient for hospitals and patients. Boston Scientific holds major franchises in both PFA and LAAC, and concomitant procedures were the main driver of WATCHMAN’s 19% growth in Q1 2026. Over the long run, the company’s ability to sell a combined AFib workflow — ablate and close in one procedure — is a genuine strategic advantage.

Driver 4: Vascular and peripheral therapies. The pending Penumbra acquisition targets mechanical thrombectomy for venous thromboembolism, peripheral arterial disease and stroke. Penumbra generated about $1.50 billion of trailing-twelve-month sales. These are large, under-penetrated procedure markets where clinical evidence is still building. Combined with Boston Scientific’s 13% growth in Interventional Cardiology & Vascular Therapies in Q2, this gives the company a second cardiovascular growth engine that does not depend on AFib.

Short-term vs. long-term dynamics. Over the next two to four quarters, the dominant forces are negative or noisy: U.S. PFA share shifting to competitors, stand-alone WATCHMAN declines, the cyber disruption, and integration costs. Over a three- to five-year horizon, the forces are positive: demographic demand, indication expansion, international PFA conversion, vascular growth from Penumbra, and restructuring savings. The investment case depends on whether investors are paid enough today to wait for the second set of forces. At 13.4x forward earnings, we think they are.

2-3. Competitive Landscape

The four large diversified cardiovascular players are Medtronic, Abbott, Johnson & Johnson and Boston Scientific. All four are now in PFA. In April, J.P. Morgan analyst Robbie Marcus said that, with J&J, Abbott and Boston Scientific all reporting Q1 results, “it’s clear Medtronic should be the big winner this quarter.” Stifel said physicians are increasingly using Medtronic’s technology, though it expects each major PFA player to keep a respectable position over the long term. Mahoney acknowledged in July that the company “did undercall the competitive pressures in the U.S. in terms of share taking.”

Large-cap medtech comparison (Finviz data, trailing twelve months)

Company	Price	Market Cap	TTM Sales	Operating Margin	Forward P/E	Key Moat
Boston Scientific (BSX)	$45.42	$65.83B	$21.00B	21.80%	13.41	PFA + LAAC leadership, physician training base
Medtronic (MDT)	$93.96	$120.19B	$37.54B	19.93%	14.69	Scale, broadest portfolio, PFA momentum
Abbott (ABT)	$104.25	$180.40B	$46.59B	16.44%	17.19	Diversification (diagnostics, nutrition, devices)
Stryker (SYK)	$302.74	$116.12B	$25.84B	24.27%	18.14	Orthopedics and capital equipment installed base
Johnson & Johnson (JNJ)	$255.79	$616.43B	$99.35B	25.85%	22.06	Pharma + MedTech, CARTO mapping installed base

Among these five companies, Boston Scientific has the lowest forward P/E, even though its operating margin sits in line with the group and its 2025 revenue grew 19.9%. A year ago the market paid up for that growth; today the stock carries a lower forward multiple than Medtronic.

Why Boston Scientific is still well positioned. Its PFA position is weakening at the margin in the U.S., but it is not collapsing: global EP sales still grew 16% in the first half of 2026 to $1.821 billion. FARAPULSE has an extensive clinical dataset, including the NEJM-published AVANT GUARD trial, and a large base of trained physicians. Competitors’ advantages are mostly about integration — J&J’s Varipulse integrates with the CARTO 3D mapping system, and Medtronic’s PulseSelect works with 3D mapping systems — and Boston Scientific has been closing that gap with its own mapping and software. In LAAC, WATCHMAN remains the established franchise, and the main question is the size of the stand-alone market, not who wins it. And in non-AFib businesses — interventional cardiology, endoscopy, neuromodulation, embolization — the company is growing at or above market rates.

3. Economic Moat Analysis

Moat Type 1: Switching Costs and Physician Training (Electrophysiology and LAAC)

Cardiac ablation and LAAC are highly skill-dependent procedures. Electrophysiologists learn a specific catheter’s handling, energy delivery settings and workflow, and hospitals invest in compatible generators, mapping systems, staff training and supply contracts. Changing platforms carries a learning curve, temporary efficiency losses and some clinical risk. This creates meaningful switching costs.

The evidence is in the numbers. Even with three well-funded competitors attacking its U.S. PFA base, Boston Scientific’s U.S. electrophysiology sales still grew 3% in Q2 2026 to $606 million, and grew 10% in the first half to $1.209 billion. Share loss has shown up as slower growth, not as falling revenue. That is what switching costs look like under pressure: they slow the erosion rather than prevent it.

WATCHMAN’s moat is even stronger. It has been on the U.S. market for over a decade and is backed by multiple randomized trials. CHAMPION-AF, presented at ACC 2026 and published in the NEJM, met all primary and secondary endpoints comparing WATCHMAN FLX with non-vitamin-K oral anticoagulants (NOACs) in a lower-risk population, with a 1.1% annualized ischemic stroke rate and significantly less bleeding through 36 months. The nuance that hurt the stock was a sub-analysis presented at Heart Rhythm 2026: among patients without prior ablation, the stroke/death/systemic embolism rate was 7.5% for the device versus 5.7% for drugs, while in patients with prior ablation it was 3.9% for both. That mixed signal, combined with reimbursement dynamics, helps explain why referrals for stand-alone procedures slowed while concomitant procedures kept growing. Few competitors can match that depth of long-term randomized data in this category. Whatever the size of the LAAC market in 2030, WATCHMAN is well positioned to remain a core part of it.

Moat Type 2: Efficient Scale and Breadth of Portfolio

Boston Scientific sells into the same hospital cardiology and gastroenterology departments across dozens of product lines. A large sales force, distribution network, sterilization capacity and contracting relationships allow it to launch new products quickly and to bundle across categories. The Q2 2026 results show the benefits: adjusted gross margin of 70.3% and adjusted operating margin of 28.4%, both up year over year despite tariff costs and slowing EP growth. Operating leverage held up even as the growth engine sputtered.

Scale also funds R&D: the company spent $1.069 billion on research and development in the first half of 2026 alone, up 10%. Few companies can fund simultaneous PFA catheter iterations, mapping software, LAAC trials, TAVR options (MiRus) and thrombectomy (Penumbra). That R&D firepower is what lets an incumbent respond to competitive launches rather than be displaced by them.

Finally, the cyberattack itself, perversely, shows a scale advantage. Within about two weeks of detection, the company reported major distribution centers shipping at or above normal levels and most global manufacturing back online. A smaller company with a single plant or a thinner supply chain would likely have faced a longer and more damaging outage.

Moat Durability Assessment

Will these moats hold over five to ten years? We see three specific threats.

First, PFA commoditization. If PFA catheters become functionally equivalent and compete mainly on mapping integration and price, Boston Scientific’s early-mover advantage fades. Counterargument: the market is growing in the mid-to-high teens, indications are expanding, and international conversion is still early. Even a smaller share of a much bigger market can support growth. Stifel’s view that every major player keeps a “respectable position” is consistent with that.

Second, the WATCHMAN evidence gap for stand-alone patients. If guidelines and payers favor anticoagulation over LAAC for patients without prior ablation, the stand-alone market could shrink permanently. Counterargument: CHAMPION-AF still met its primary endpoints, shows meaningful bleeding reduction, and concomitant procedures are growing. Management has already assumed no WATCHMAN growth in 2027, so this risk is at least partly reflected in guidance.

Third, execution and governance. Two guidance cuts and a cyberattack in one year raise legitimate questions about forecasting and operational controls. Counterargument: the leadership changes, the restructuring program and the deep bench of long-tenured operators suggest the board is responding. On balance, we rate the moat as narrowing but still wide: the company’s competitive advantages remain real, but the excess returns of 2024–2025 were partly a temporary first-mover windfall that will not fully return.

투자 분석 이미지 — Photo by Jair Lázaro on Unsplash

4. Financial Analysis

Income statement trend (company filings; figures in USD millions except per share)

Metric	FY2024	FY2025	H1 2025	H1 2026	TTM (Q2’26)
Net Sales	$16,747	$20,074	$9,724	$10,646	$21,000 (approx.)
YoY Growth	—	+19.9%	—	+9.5%	—
Gross Profit	$11,490	$13,854	$6,633	$7,462	—
Gross Margin	68.6%	69.0%	68.2%	70.1%	66.36% (Finviz)
GAAP Operating Income	$2,603	$3,613	$1,740	$2,279	—
Net Income (to common)	$1,853	$2,898	$1,471	$2,247	$3,670 (approx.)
GAAP Diluted EPS	$1.25	$1.94	$0.98	$1.51	$2.47
Adjusted EPS	$2.51	$3.06	—	—	—

Note: TTM sales and income from Finviz ($21.00B / $3.67B) reconcile to FY2025 minus H1 2025 plus H1 2026. Finviz’s TTM gross margin uses a different cost basis than the GAAP table above.

The story behind each period.

FY2024 → FY2025 (+19.9% sales, +56% GAAP net income). This was the peak of the FARAPULSE and WATCHMAN cycle. Cardiovascular grew 23% reported (21% organic), with WATCHMAN up nearly 30% to $1.96 billion. Adjusted EPS rose 22% to $3.06, beating the high end of guidance. The market capitalized this growth at a premium multiple and the stock reached its highs.

H1 2026 (+9.5% sales). Growth halved. Electrophysiology slowed from explosive rates to 16% for the half and roughly 9% in Q2. WATCHMAN grew 11% in the half but only 4% in Q2 as stand-alone procedures fell. Yet profitability improved: GAAP operating income rose 31%, gross margin expanded 190 basis points, and H1 GAAP net income rose 53% (helped by a tax benefit in Q1). Q2 adjusted EPS of $0.86 beat the company’s guidance range of $0.82–$0.84. Q2 also included about $80 million in IEEPA tariff refunds, which the company excludes from adjusted results.

Guidance history in 2026.

Date	Net Sales Growth (reported)	Adjusted EPS
February 4	10.5% – 11.5%	$3.43 – $3.49
April 22	7% – 8.5%	$3.34 – $3.41
July 29	5.5% – 6.5%	$3.28 – $3.32
September 7	“Unlikely to meet” July ranges due to cyber incident	Update on October 28

Q3 2026 guidance, issued in July before the attack, called for 3–5% organic growth and adjusted EPS of $0.80–$0.82. Investors should expect a miss against that on October 28, given that disruption began on August 25 — more than five weeks before quarter-end.

Key operating metrics to watch.
– U.S. EP growth: 3% in Q2 2026. This is the single most important share indicator.
– International EP growth: 23% in Q2. This shows where PFA conversion is still running.
– WATCHMAN: management guides to flat-to-low-single-digit growth for 2026 with a mid- to high-single-digit decline in the second half, and assumes no growth in 2027.
– Non-AFib businesses: growing about 6% in aggregate according to management.

Balance sheet and cash flow (June 30, 2026).
– Cash and equivalents: $539 million (down from $1.965 billion at year-end 2025 after the ASR, MiRus and Nalu payments).
– Current debt obligations: $1.709 billion; long-term debt: $10.915 billion. Total debt is about $12.6 billion and net debt about $12.1 billion.
– Stockholders’ equity: $24.93 billion. Finviz shows Debt/Equity of 0.51.
– Operating cash flow: $1.822 billion in H1 2026 (flat year over year), less capital expenditures of $372 million, gives free cash flow of about $1.45 billion for the half — roughly $2.9 billion annualized (est.).

The Penumbra financing question. Closing Penumbra requires roughly $11 billion of cash, which the company has said it will fund with cash on hand and new debt. That would push net debt toward the low-$20 billion range (est.). Against roughly $6 billion of annual adjusted EBITDA (est., based on FY2025 adjusted operating income of $5.612 billion plus depreciation), pro forma leverage would be roughly 3.5–4x (est.), elevated for a company with a falling share price. Deleveraging would likely take two to three years and would limit buybacks in that period. There is also a share-count effect: because the stock component uses a fixed 3.8721 exchange ratio on about 27% of consideration, the dilution in share count is fixed even though the BSX share price has fallen, while the dollar value of the stock component has shrunk.

Margin expansion story. Despite the slowdown, Boston Scientific remains a margin-expansion story. Adjusted operating margin rose from about 27% in 2024 to 28% in 2025 and 28.4% in Q2 2026. The 2026 restructuring plan (approved July 21) carries $700–800 million of pre-tax charges through 2029 and targets about $500 million of gross annual pre-tax savings, a substantial portion of which management plans to reinvest. Even if half of those savings fall to the bottom line, that adds roughly 1 percentage point of operating margin on today’s sales base.

5. Valuation: What Is Boston Scientific Stock Worth After the Cyberattack?

Current valuation snapshot (Finviz):
– Price: $45.42
– Market cap: $65.83 billion; shares outstanding: 1.45 billion
– EPS (TTM, GAAP): $2.47 → P/E 18.42
– EPS next year (consensus): $3.39 → Forward P/E 13.41
– P/B: 2.64; P/S: 3.14
– ROE: 15.52%; Debt/Equity: 0.51
– Consensus analyst target: $58.11 (+27.9% upside)

Method: forward P/E on consensus 2027 EPS, cross-checked with free cash flow yield. P/E is appropriate here because Boston Scientific is consistently profitable and reports adjusted EPS that excludes amortization and one-time charges. We use the consensus forward EPS of $3.39 as the base input.

Step 1 — Choose the earnings base. Consensus forward EPS of $3.39 is only modestly above the company’s pre-cyberattack 2026 guidance of $3.28–$3.32. That looks reasonable but not conservative: it implies 2–3% growth from the original 2026 run-rate, with restructuring savings and buybacks offsetting the WATCHMAN decline and EP share loss. It does not include Penumbra, which would likely be modestly dilutive to adjusted EPS in year one because of interest costs (est.).

Step 2 — Choose the multiple. Large-cap medtech peers in the table above trade at 14.7x (Medtronic) to 22.1x (Johnson & Johnson) forward earnings; excluding pharma-heavy J&J, the pure-play device range is 14.7x–18.1x. Boston Scientific historically traded at a premium to the group because it grew faster. With growth now slowing to mid-single digits, a premium is no longer justified, but a discount to Medtronic (which has a slower-growing, lower-margin portfolio) is also hard to defend once the cyber disruption passes. We use 16x for the base case — between Medtronic and Abbott, and still well below the stock’s historical range.

Step 3 — Calculate the base case. $3.39 × 16 = $54.24, rounded to $54, or about 19% upside from $45.42.

Step 4 — Cross-check with free cash flow. Annualized H1 2026 free cash flow of about $2.9 billion (est.) on a $65.83 billion market cap is a 4.4% FCF yield. At our $54 target, market cap would be about $78 billion and the FCF yield about 3.7% — reasonable for a company still growing mid-single digits with expanding margins.

Scenario analysis

Scenario	2027 EPS	Multiple	Target Price	vs. $45.42	Assumptions
Bull	$3.55	20x	$71	+56%	EP share stabilizes in H1 2027; international PFA keeps 20%+ growth; Penumbra closes cleanly; restructuring savings fall through
Base	$3.39	16x	$54	+19%	Consensus EPS holds; cyber impact contained to 2026; WATCHMAN flat in 2027
Bear	$2.90	11x	$32	-30%	U.S. EP declines outright; WATCHMAN stand-alone erosion deepens; cyber costs and Penumbra interest cut EPS; multiple compresses further

A simple probability weighting (50% base, 25% bull, 25% bear) gives about $53, or roughly 16% expected upside.

Versus consensus. The Street’s average target of $58.11 is above our $54 base case. Consensus targets are falling — Bernstein cut its target to $54 from $60 in early October, with other published targets from Baird ($56), Leerink ($60) and Piper Sandler ($65) — so the average still includes stale, pre-cyberattack estimates. We think the consensus EPS number of $3.39 is more at risk of downward revision after October 28 than upward, so we stay below the Street. Where we agree with the Street is direction: at 13.4x forward earnings, the stock already prices in an extended period of weak growth.

What the price implies. At $45.42 and a 16x “fair” peer multiple, the market is effectively pricing 2027 EPS of about $2.84 — roughly 16% below consensus. That is close to our bear-case earnings assumption. But that reading needs the multiple to recover from 13.4x to 16x. Our full bear case, with 11x on $2.90, still points to about $32 (-30%).

6. Risk Factors

Risk 1: Continued U.S. electrophysiology share loss. This is the biggest risk. U.S. EP grew only 3% in Q2 2026, and management has admitted it underestimated competitive pressure. If Medtronic’s PulseSelect and Affera platforms, J&J’s Varipulse with CARTO integration, and Abbott’s Volt and TactiFlex Duo keep gaining share, U.S. EP revenue could start declining year over year in 2027. Because EP was the company’s largest growth engine and carries high incremental margins, every point of lost share has an outsized effect on EPS. Pricing pressure is a related risk: as PFA becomes a four-player market, hospitals gain leverage to negotiate catheter prices down. The early signals to watch on October 28 are the U.S. EP growth rate (disentangled from cyber disruption), comments on new account wins and losses, and any update on mapping-system integration. A negative U.S. EP growth print in Q4 2026 or Q1 2027 would invalidate our base case.

Risk 2: Permanent shrinkage of the stand-alone WATCHMAN market. The CHAMPION-AF sub-analysis, showing a higher stroke/death/systemic embolism rate for the device than drugs among patients without prior ablation, gives cardiologists and payers a reason to favor anticoagulation for stand-alone patients. Stand-alone procedures already declined in the low-to-mid teens in the U.S. in Q2. If guideline committees or CMS coverage decisions move against stand-alone LAAC, the decline could persist for years. WATCHMAN is roughly 9% of sales but carries premium margins, so a multi-year decline would weigh on both growth and margins. Management has already assumed no WATCHMAN growth in 2027; the risk is that the actual outcome is a decline rather than flat. Watch for guideline updates, CMS national coverage determinations and the growth rate of concomitant procedures, which partly offset stand-alone weakness.

Risk 3: Cyberattack aftershocks and credibility. The September 7 8-K said the investigation was ongoing and the timeline for full recovery was uncertain. The company has not disclosed the financial impact. Risks include a bigger-than-expected Q3/Q4 revenue loss, customers permanently shifting some orders to competitors during the outage, remediation and legal costs, and possible regulatory scrutiny. Beyond the direct costs, there is a credibility problem: this would be the third guidance reset in 2026. Investors already burned twice may refuse to believe a new 2027 framework until it is proven over several quarters, keeping the multiple compressed. We would view any statement on October 28 that customer losses are permanent, or that systems are still not fully restored, as a material negative.

Risk 4: Penumbra deal and leverage. The FTC’s Second Request is still outstanding. A challenge or a remedy requirement could delay or derail the deal; a completed deal adds about $11 billion of cash consideration, pushing leverage to roughly 3.5–4x EBITDA (est.) at a time when organic growth is slowing. Either outcome creates uncertainty: deal failure would remove a growth driver, while completion would constrain buybacks and add integration risk.

7. Conclusion and Exit Plan

Rating: Buy (higher-risk, staged entry)

Boston Scientific now trades at the lowest forward P/E (13.4x) of the five large-cap medtech companies in our peer table, below Medtronic’s 14.7x. The causes are real: competition in PFA, a softer WATCHMAN market and a damaging cyberattack. But the price reflects bear-case earnings only if the multiple recovers to ~16x; the full bear case still implies ~30% downside. Meanwhile, the business still grows in its non-AFib franchises, still expands margins, still generates about $2.9 billion of annualized free cash flow (est.), and still holds major positions in EP and LAAC. We think the risk-reward on Boston Scientific stock after the cyberattack favors patient buyers, but this is not a stock to buy all at once before October 28.

Entry price range: $40–$47.
– Begin a starter position (about one-third of the intended size) in the current $45–$47 range.
– Add another third after the October 28 report if management quantifies the cyber impact and gives a credible 2027 framework, even if Q3 numbers are weak.
– Add the final third on any post-earnings flush toward $40, where the stock would trade below 12x consensus forward EPS.

Exit conditions:
– Target achieved: trim half at our $54 base-case target; sell the remainder near the $71 bull-case target if EP share has stabilized.
– Fundamental break: sell if U.S. EP sales decline year over year for two consecutive quarters, if the company guides 2027 adjusted EPS below $3.00, or if the company discloses that the cyberattack caused lasting customer losses.
– Time-based: reassess after Q4 2026 results in early February 2027, when the first full-year 2027 guidance and Penumbra status should be clear. If the thesis has not started playing out by the Q2 2027 report, re-underwrite from scratch.

Summary

Item	Detail
Company	Boston Scientific (BSX)
Current Price	$45.42
Target Price	$54 (base) / $71 (bull) / $32 (bear)
Upside	19% (base)
Rating	Buy (staged entry)
Key Thesis	13.4x forward EPS already discounts much of the EP share loss and WATCHMAN slowdown; cyber disruption is a 2026 timing issue
Main Risk	Accelerating U.S. pulsed field ablation share loss to Medtronic, J&J and Abbott

For investors deciding what to do with Boston Scientific stock after the cyberattack, the October 28 report is the next checkpoint. The headline numbers are likely to be weak. What matters is whether management can show that the disruption is temporary, that U.S. EP share loss is slowing, and that 2027 earnings power is still near consensus. If those three conditions hold, today’s price looks like a good entry into a high-quality franchise.

—

Disclaimer

This content is general investment information provided to an indefinite/unspecified audience by a quasi-investment advisory business registered under Korea’s Financial Investment Services and Capital Markets Act, and is not personalized 1:1 investment advice tailored to any individual investor. This analysis is for informational purposes only and is not a solicitation to invest. All investment decisions and their consequences rest solely with the investor. The estimates and assumptions in this report are as of the writing date (2026-10-20) and may not materialize depending on market conditions and geopolitical variables. Financial data used reflects sources such as company filings and analyst consensus, and the scenarios and price targets represent the author’s conservative assessment. All investments carry the risk of principal loss, and past performance or analytical track record does not guarantee future results. As of the writing date, the author does not hold a position in this stock. The author’s holdings and positions may change without prior notice depending on market conditions.